10x Genomics (NASDAQ:TXG) Insider Sells $157,377.00 in Stock

10x Genomics (NASDAQ:TXG) insider Benjamin Hindson sold 8,283 shares of 10x Genomics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $157,377.00. Following the sale, the insider owned 432,605 shares in the company, valued at approximately $8,219,495. The trade was a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

10x Genomics Trading Down 5.3%

Shares of NASDAQ:TXG traded down $1.06 during midday trading on Tuesday, reaching $19.07. 5,111,275 shares of the company were exchanged, compared to its average volume of 3,246,832. The stock has a market cap of $2.41 billion, a PE ratio of -30.76 and a beta of 2.13. The business’s fifty day moving average is $13.55 and its two-hundred day moving average is $12.44. 10x Genomics has a one year low of $6.78 and a one year high of $20.34.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The business had revenue of $149.00 million for the quarter, compared to analysts’ expectations of $142.50 million. During the same quarter in the previous year, the company earned ($0.30) EPS. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. 10x Genomics has set its Q4 2025 guidance at EPS. As a group, sell-side analysts expect that 10x Genomics will post -1.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TXG. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a report on Monday, November 17th. Morgan Stanley decreased their price target on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 12th. Piper Sandler lifted their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. Barclays boosted their target price on shares of 10x Genomics from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, UBS Group increased their price target on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $14.88.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TXG. Allworth Financial LP boosted its holdings in shares of 10x Genomics by 150.4% in the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock valued at $26,000 after purchasing an additional 1,364 shares during the last quarter. True Wealth Design LLC boosted its holdings in 10x Genomics by 1,552.5% in the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock valued at $42,000 after acquiring an additional 3,369 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in 10x Genomics by 153.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock valued at $45,000 after acquiring an additional 3,119 shares during the last quarter. US Bancorp DE grew its position in 10x Genomics by 314.5% during the first quarter. US Bancorp DE now owns 5,973 shares of the company’s stock valued at $52,000 after acquiring an additional 4,532 shares during the period. Finally, Abich Financial Wealth Management LLC acquired a new stake in 10x Genomics during the third quarter worth about $56,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.